AI in Biopharma

Seven essential reads across Scrip, In Vivo, and Pink Sheet — covering the commercial deal flows, strategic investment frameworks and regulatory enforcement positions shaping how biopharma navigates AI in 2026.

• When regulators publish guidance, the document tells you what changed. Our journalists tell you why it happened, how the industry will respond, and what it means for your next move.
• The executives, investors and officials shaping biopharma's AI decade don't issue press releases. We interview them directly and translate what they say into intelligence your team can act on.
• Anyone can summarize the news. Knowing whether it signals a genuine market shift, an unpriced risk or a closing window requires the kind of context that doesn't come free.